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Abstract
Introduction Identifying critically ill patients most likely to benefit
from pre-emptive therapies will become increasingly important if
therapies are to be used safely and cost-effectively. We sought
to determine whether a predictive model could be constructed
that would serve as a useful decision support tool for the pre-
emptive management of intensive care unit (ICU)-related
anemia.
Methods Our cohort consisted of all ICU patients (n = 5,170)
admitted to a large tertiary-care academic medical center during
the period from 1 July 2000 to 30 June 2001. We divided the
cohort into development (n = 3,619) and validation (n = 1,551)
sets. Using a set of demographic and physiologic variables
available within six hours of ICU admission, we developed
models to predict patients who either received late transfusion
or developed late anemia. We then constructed a point system
to quantify, within six hours of ICU admission, the likelihood of
developing late anemia.
Results Models showed good discrimination with receiver
operating characteristic curve areas ranging from 0.72 to 0.77,
although predicting late transfusion was consistently less
accurate than predicting late anemia. A five-item point system
predicted likelihood of late anemia as well as existing clinical trial
inclusion criteria but resulted in pre-emptive intervention more
than two days earlier.
Conclusion A rule-based decision support tool using
information available within six hours of ICU admission may lead
to earlier and more appropriate use of blood-sparing strategies.
Introduction
Most intensive care therapies are prescribed in response to
the development of organ dysfunction or other unwanted
events. For example, antibiotics are prescribed when a patient
develops sepsis, or tidal volumes are lowered when a patient
develops acute respiratory distress syndrome (ARDS) [1]. In
other arenas of medicine, therapies are much more commonly
provided to populations who are at risk of unwanted events, in
the hope of future benefit. For example, antihypertensives and
lipid-lowering agents are given to prevent cardiovascular dis-
ease long before any hint of the disease has ever manifested.
It is likely that similar pre-emptive strategies will reap gains in
the intensive care unit (ICU). For example, it seems that use of
low tidal volumes in patients at risk of ARDS reduces the like-
lihood of their subsequently developing ARDS [2]. However,
critically ill patients are fragile and complex, so broad use of
early therapies with a theoretical hope of avoiding or mitigating
downstream consequences will probably need to be balanced
against the costs and risks of the therapies themselves. Thus,
strategies to identify the candidates most likely to benefit will
become increasingly important if therapies are to be used
safely and cost-effectively.
In this article we chose anemia of critical illness as an illustra-
tive example of a condition that one might want to manage pre-
emptively. Trials are currently ongoing to assess whether treat-
ment with recombinant human erythropoietin (rHuEPO) can
mitigate anemia-associated morbidity or mortality. If the out-
come of these trials is positive, we will be faced with an inter-
esting challenge. Specifically, we will have a therapy that is
expensive, associated with small but potentially important side
effects, unlikely to offer any benefit to patients who have short
ICU courses and are at no risk of anemia of critical illness, and
yet only able to produce significant improvements in serum
hemoglobin levels after several days of treatment. Therefore,
to be most effective it must be given early in the ICU course,
ARDS = acute respiratory distress syndrome; ICU = intensive care unit; rHuEPO = recombinant human erythropoietin; ROC = receiver operating 
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and to be most efficient it must be given only to the subset of
ICU patients who will end up incurring a prolonged hospital
stay and developing anemia. The dilemma of finding the right
subset of patients before they have developed the outcome of
interest is a classic decision-making problem, with similarities
to other situations that may soon arise in critical care, such as
early tracheostomy [3] or the prophylactic use of antidepres-
sants [4].
The goal of this paper was to determine whether a predictive
model could be constructed that would serve as a useful deci-
sion support tool for the pre-emptive management of ICU-
related anemia. We stress that this exercise is only theoretical
at this point, because there is insufficient evidence to recom-
mend rHuEPO as therapy for anemia of critical illness. How-
ever, we believe the exercise sheds light on the potential
opportunities for similar models for other pre-emptive manage-
ment strategies in the ICU.
Materials and methods
Our approach was to build and validate a model-based rule
that used information available within six hours of ICU admis-
sion to predict the likelihood that a patient would have a pro-
longed hospital course complicated by anemia. We then
compared the potential consequences of a prescription strat-
egy that relied on the rule with those of a strategy that uses the
existing clinical trial inclusion criteria [5] and with those of a
broad-based ICU prescription strategy.
Patients and data sources
For our study cohort we selected all ICU patients admitted
during the period from 1 July 2000 to 30 June 2001 at the Uni-
versity of Pittsburgh Medical Center, a hospital with more than
120 ICU beds caring for adult medical, surgical, trauma, neu-
rologic, and solid-organ transplant patients. We obtained
information from several computerized databases, including
administrative discharge data, laboratory data, itemized billing
records, and a detailed bedside database containing the fol-
lowing prospectively collected data for all ICU patients: demo-
graphics, admission diagnosis, physiologic data, and
interventions (medications, fluids and blood products,
mechanical ventilation, and renal replacement). To preserve
patient confidentiality, all data were de-identified and linked by
an honest broker. The data were cleaned (purged of inconsist-
ent and/or nonsense values), organized, and merged to create
files for the analysis. We then generated composite variables,
such as the presence of organ dysfunction, from detailed
physiologic data. Data were manipulated as a relational data-
base in Microsoft FoxPro 6.0. The University of Pittsburgh
Institutional Review Board approved the study.
Modeling and statistical analyses
The cohort was divided into development (two-thirds of
cohort) and validation (one-third of cohort) sets. Using a set of
demographic and physiologic variables available within six
hours of ICU admission, we developed two predictive models
using logistic regression. The first model was developed to
identify patients who received 'late transfusion', namely those
who received red cell transfusion(s) 7 days or more after ICU
admission. The second model was developed to identify
patients who developed 'late anemia', namely those whose
actual or predicted hemoglobin reached 7 g/dl or less at seven
days or more after ICU admission. The threshold of 7 g/dl was
based on the randomized controlled trial by Hebert and col-
leagues [6], which found a lower hospital mortality for subjects
transfused below this value compared with a more liberal (10
g/dl) transfusion threshold. For patients with pre-transfusion
hemoglobin concentrations of more than 7 g/dl, we extrapo-
lated these values to determine who would have reached 7 g/
dl by using the mean of individual slopes of hemoglobin con-
centrations. Individual slopes were constructed from the cal-
culated day-to-day decrease in hemoglobin in patients not
receiving transfusions [7].
Independent predictors eligible for inclusion in the two models
were as follows: age (less than 65 years, 65 years or more),
gender, race (white, black or other), comorbidity [8], body
mass index, medical or surgical admission, emergency sur-
gery, trauma, and the following data obtained within six hours
of ICU admission: minimum hemoglobin, red cell transfusion
(yes/no), creatinine (less than 1.6 mg/dl, 1.6 mg/dl or more),
international normalized ratio (1.9 or less, more than 1.9), arte-
rial blood lactate (1.5 mg/dl or less, more than 1.5 mg/dl), and
need for mechanical ventilation or vasopressors. Model dis-
crimination and calibration were tested by using the receiver
operator characteristic (ROC) curve area and the Hosmer–
Lemeshow test. In secondary analyses, we developed models
using data available within 24, 48, and 72 hours of ICU admis-
sion. Using the 6-hour model for late anemia, we constructed
a point system to quantify, on the first ICU day, the likelihood
of their reaching a hemoglobin value of 7 g/dl or less at 7 days
or more after ICU admission and therefore being a suitable
candidate for a blood-sparing strategy such as rHuEPO. We
then compared the potential consequences of a prescription
strategy that relied on the rule with those of a strategy that
uses the existing clinical trial inclusion criteria (ICU length of
stay 3 days or more, age 18 years or more, and hematocrit less
than 38%) [5] and with those of a broad-based ICU prescrip-
tion strategy. All data analyses were performed and models
developed with SPSS 11.5 (Chicago, IL, USA). We assumed
statistical significance for differences between groups or
model coefficients at p < 0.05.
Results
Patient characteristics
A total of 5,170 ICU patients were admitted from 1 July 2000
to 30 June 2001 (Table 1), with 887 (17.2%) and 1,034
(20.0%) in the late transfusion and late anemia groups,
respectively. There was a fair degree of overlap between the
two groups (Figure 1). Within six hours of ICU admission,Available online http://ccforum.com/content/10/1/R39
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Table 1
Demographic and clinical variables
Variable All patients Late transfusion No late transfusion Late anemia No late anemia
Subjects (n) 5,170 887 4,283 1,034 4,136
Age, years (mean ± SD; median) 60.5 ± 17.4; 62.5 60.9 ± 17.4; 62.2 60.4 ± 17.4; 62.6 60.1 ± 17.2; 61.5 60.6 ± 17.5; 62.8
Age 65 years or more (%) 47.1 46.1 47.3 44.3* 47.8
Race (%)
White 85.3 85.3 85.2 85.6 85.2
Black 8.4 8.3 8.5 8.8 8.3
Others and unknown 6.3 6.3 6.3 5.6 6.5
Gender (percentage females) 43.6 44.5 43.5 44.6 43.4
Co-morbiditya (%) 51.5 57.7c 50.3 57.3c 50.1
Diabetes 17.5 17.5 17.5 17.2 17.5
Pulmonary disease 9.8 12.3c 9.3 10.7 9.6
Renal disease 0.2 0.8c 0.1 0.4 0.2
Liver disease 7.3 14.3c 5.9 13.8c 5.7
Peripheral vascular disease 5.0 6.5c 4.6 4.7 5.0
Cerebrovascular disease 1.8 1.8 1.8 2.1 1.7
Myocardial infarction 7.2 4.5c 7.7 5.7c 7.5
BMI (mean ± SD; median) 27.7 ± 7.4; 26.5 27.0c ± 7.3; 25.7 27.9 ± 7.4; 26.6 27.3c ± 7.1; 25.9 27.9 ± 7.4; 26.6
Medical (%) 41.2 21.1c 45.4 19.2c 46.7
Emergency surgery (%) 17.4 15.1c 17.9 17.4 17.4
Trauma case (%) 12.0 13.5 11.7 14.9c 11.2
Admission diagnosisb (%)
Medical
Cardiovascular 3.9 3.6 3.9 3.6 3.9
Respiratory 7.1 7.8 6.9 5.5c 7.5
Gastrointestinal 5.5 6.4 5.3 7.5c 5.0
Neurologic 7.8 6.5 8.1 4.8c 8.6
Sepsis 2.4 4.5c 2.0 3.5c 2.2
Nonoperative trauma 4.9 6.1 4.6 5.0 4.9
Metabolic 2.1 0.9c 2.3 0.8c 2.4
Renal 0.3 0.2 0.3 0.3 0.3
Other medical 0.9 0.9 0.8 0.6 0.9
Surgical
Cardiovascular 17.8 8.5c 19.8 13.0c 19.1
Respiratory 1.9 1.8 1.9 2.0 1.9
Gastrointestinal 3.7 4.5 3.5 4.6 3.5
Neurologic 3.1 2.6 3.2 3.5 3.0
Operative trauma 2.7 4.1c 2.4 5.4c 2.0
Other surgical 1.1 1.2 1.1 1.6 1.0Critical Care    Vol 10 No 1    Milbrandt et al.
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patients in either group were significantly more likely than
those who did not belong to each group to have at least one
comorbidity, lower body mass index, surgical admission type,
transfusion, mechanical ventilation, inotrope use, and higher
creatine, international normalized ratio, and lactate (all p <
0.05). In addition, those in the late transfusion group were less
likely to have undergone emergent surgery, whereas those in
the late anemia had lower initial hemoglobin values and were
more likely to have been less than 65 years of age and admit-
ted for trauma.
Model development and validation
The population was divided into development (n = 3,619) and
validation (n = 1,551) cohorts. Independent predictors for late
transfusions and late anemia are provided in Table 2. The
ROC curve areas and Hosmer–Lemeshow test p values for
the development and validation cohorts for late transfusion
were 0.75 (p = 0.06) and 0.72 (p = 0.46), respectively, and
the corresponding values for late anemia were 0.77 (p = 0.01)
and 0.74 (p = 0.05). The ROC curve for the development
cohort of the late anemia model is depicted in Figure 2a. This
figure also illustrates the correspondence between sensitivity
and the fraction of the study population that exceeds the pos-
itivity threshold and is therefore considered at risk for late ane-
mia for a given sensitivity level. Higher sensitivity results in
lower specificity, corresponding to a higher proportion of the
population being considered at risk. For example, a desired
sensitivity of 60% entails declaring a threshold for positivity
corresponding to a probability of late anemia of 22% or more
Figure 1
Venn diagram of patient groups Venn diagram of patient groups. More patients met criteria for late ane-
mia (group B, n = 1,034) than for late transfusion (group A, n = 887). 
More than one-quarter (1,340/5,170; 25.9%) of all patients admitted to 
the intensive care unit met criteria for at least one group. Although there 
is considerable overlap, a significant proportion of patients (759/5,170; 
14.7%) met only one set of criteria.
Unknown 34.9 40.4c 33.7 38.2c 34.0
APACHE III score (mean ± SD; median) 48.2 ± 25.1; 44.0 56.4c ± 23.9; 
54.0
46.7 ± 25.0; 42.0 54.9c ± 23.6; 
51.0
46.7 ± 25.1; 42.0
MV at any time (%) 30.6 56.0c 25.4 50.4c 25.7
ICU LOS, days (mean ± SD; median) 6.3 ± 9.7; 3.0 17.8c ± 16.9; 
14.0
3.9 ± 4.7; 2.0 15.5c ± 16.2; 
11.0
4.0 ± 5.2; 2.0
Hospital LOS days (mean ± SD; median) 15.0 ± 16.3; 9.0 33.8c ± 24.0; 
27.0
11.1 ± 10.7; 8.0 30.0c ± 22.7; 
24.0
11.2 ± 11.6; 8.0
Hospital mortality (%) 12.9 20.3c 11.4 13.5 12.7
Physiologic and therapeutic measures 
within 6 hours of ICU admission
Hemoglobin, g/dl (mean ± SD; 
median)
9.6 ± 4.7; 10.7 9.5 ± 3.6; 10.0 9.6 ± 4.9; 10.9 9.1c ± 3.6; 9.7 9.7 ± 4.9; 11.1
Lactate more than 1.5 mg/dl (%) 14.7 26.5c 7.7 26.3c 11.8
Creatinine at least 1.6 mg/dl (%) 15.7 26.0c 13.5 22.7c 13.9
INR more than 1.9 (%) 5.7 10.1c 4.8 10.0c 4.7
Inotropes (%) 10.6 17.7c 9.1 17.3c 8.9
Mechanical ventilation (%) 16.3 23.9c 14.8 22.2c 14.8
Transfusion (%) 8.3 11.2c 7.7 17.2c 6.1
Late transfusion, transfused 7 days or more after admission to intensive care unit; late anemia, reached or would have reached 7.0 g/dl at 7 days 
or more after admission to intensive care unit. APACHE, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; ICU, intensive 
care unit; LOS, length of stay; MV, mechanical ventilation; INR, international normalized ratio. aAny co-morbidity, as measured in accordance with 
Charlson–Deyo procedures for the index admission with International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
discharge diagnoses. bAdmission diagnosis, which represents the condition most likely to be responsible for ICU admission as reported in the 
electronic medical record, was not available for 35% of patients. Because of rounding, totals may not equal 100%. cp < 0.05 between patients 
belonging to group of interest and those who did not belong to this group.
Table 1 (Continued)
Demographic and clinical variablesAvailable online http://ccforum.com/content/10/1/R39
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(T'), resulting in 34% of the population exceeding this pre-
dicted probability and thus being considered at risk for late
anemia (P') and potential candidates for intervention. For a
desired sensitivity of 90%, the corresponding probability of
late anemia would be 10% or more, resulting in the judging of
64% of the population to be at risk. Higher discrimination; in
other words a greater ROC curve area, would allow a smaller
proportion of the population to be considered at risk for a
given sensitivity. In secondary analyses we constructed mod-
els that included the same risk factors but evaluated within 24,
48, and 72 hours of ICU admission. These models showed
modest improvements in discrimination (Table 3), yet they
resulted in progressively greater delays in identifying patients
at risk of late transfusion or late anemia. It is noteworthy that
predicting late transfusion was consistently less accurate than
predicting late anemia.
Development of an ICU anemia score
We wished to improve the practicality and possible clinical
utility of a prediction rule for patients at risk for late anemia who
might benefit from a blood-sparing strategy. Using the late
anemia model we constructed a point system to calculate,
within 6 hours of ICU admission, the likelihood of reaching the
outcome of interest, a hemoglobin value of 7 g/dl or less at 7
days or more after ICU admission. We assumed that a base-
line hemoglobin of 14 g/dl or more and the absence of any risk
predictors would amount to a minimum score of zero and thus
a minimum chance for reaching the outcome. The maximal
score of 51 corresponds to a baseline hemoglobin of 7 and
the presence of all risk factors. Interestingly, this maximal
Figure 2
Receiver operating characteristics of late anemia prediction model and  correspondence with point system Receiver operating characteristics of late anemia prediction model and 
correspondence with point system. (a) The receiver operating charac-
teristic (ROC) of the model predicting late anemia. Higher sensitivity 
(S) is associated with a lower threshold for positivity (T', probability of 
meeting criteria for late anemia). Accordingly, a higher proportion of the 
population will be declared to meet late anemia criteria (P') as specifi-
city decreases. For example, a desired sensitivity of 60% would entail 
declaring a threshold for positivity corresponding to a probability of late 
anemia of 22% or more (T'). This results in 34% of the population 
exceeding this predicted probability and thus at risk for late anemia (P'). 
(b) Correspondence between intensive care unit (ICU) anemia points 
(see the text) and the ROC curve. Determining a lower point threshold 
of unacceptable risk of late anemia entails a trade-off between higher 
sensitivity and the willingness to declare a higher proportion of the pop-
ulation at risk. Setting a threshold of 21 points, which would achieve a 
sensitivity of 60% in identifying patients meeting criteria for late anemia, 
would result in considering intervention in 34% of the population (a). 
On the assumption that the proposed intervention is recombinant 
human erythropoietin, considering all ICU patients for treatment would 
result in 100% sensitivity, but no specificity (point A). Using inclusion 
criteria for the Corwin study results in 77% sensitivity and 65% specifi-
city as illustrated by point B (see the text and Table 4), which is compa-
rable to the point-based system. The ICU anemia score permits earlier 
intervention with comparable predictive power.
Table 2
Risk factors for late transfusion or late anemia from 
multivariable models
Risk factora Odds ratio (95% confidence interval)
Late transfusion Late anemia
Abnormal lactate (> 
1.5 mg/dl)
1.64 (1.28–2.09) 1.79 (1.41–2.26)
Transfused 0.64 (0.45–0.87) -
Surgical patient 2.51 (1.86–3.40) 2.90 (2.19–3.83)
Non-emergent 
surgery








Inotropic support - 1.69 (1.29–2.21)
Late transfusion, transfused 7 days or more after admission to 
intensive care unit; late anemia, reached or would have reached 7.0 
g/dl at 7 days or more after admission to intensive care unit. aWorst 
value recorded up to 6 hours after admission to intensive care unit. 
bCalculated as g/dl lower than 14 g/dl, with zero deficit defined as a 
baseline hemoglobin of at least 14 g/dl.Critical Care    Vol 10 No 1    Milbrandt et al.
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score corresponds to a predicted probability of outcome of
0.81 as opposed to 1.00, reflecting that patients with an
excessive burden are likely to die before 7 days. The ICU ane-
mia point scheme, described in Table 4, demonstrated good
discrimination, with an ROC curve area of 0.74. The corre-
spondence between the sensitivity of the model in identifying
patients that suffered late anemia and the corresponding
number of points is shown in Figures 2b and 3.
Recommending a specific threshold beyond which patients
should be considered at risk for late anemia and thus as can-
didates for a blood-sparing strategy depends on the cost and
possible side effects of this strategy. Willingness to broaden
the criteria to implement the strategy is more forthcoming with
a low risk/low cost strategy. From Figure 2b, one might con-
sider as candidates patients with ICU anemia scores in excess
of 12 (more than 90% sensitivity; 64% of the population are
candidates). Costlier or riskier strategies would dictate higher
thresholds (for example an ICU anemia score of more than 21;
more than 60% sensitivity; 34% of the population are candi-
dates).
Potential consequences of point-based system and 
other prescriptive strategies
On the assumption that the proposed intervention is rHuEPO,
treatment of all comers regardless of baseline or clinical char-
acteristics resulted in 100% of patients who needed the inter-
vention getting it, but also 100% of patients who did not
(Table 5 and Figure 2b, point A). Application of the Corwin trial
inclusion criteria [5] to patients in our cohort correctly targeted
for treatment 77.4% (800/1,034) of those who were destined
to develop late anemia (Table 5). However, it also resulted in
the treatment of 35.5% (1,470/4,136) of patients who did not
develop late anemia. When plotted against the ICU anemia
score ROC curve, the prediction offered by the Corwin criteria
(Figure 2b, point B) falls near the curve, indicating that the
Corwin criteria perform as well as the point-based system.
However, the Corwin criteria require a patient to be in the ICU
for 3 days before initiating treatment, resulting in a delay of
more than 2 days in treatment initiation in comparison with the
point-based system, which depends only on data available
within 6 hours of ICU admission.
Discussion
Using information available within six hours of ICU admission,
we were able predict the likelihood of late anemia with reason-
able accuracy, suggesting a window of opportunity for the
early identification of patients who might benefit from transfu-
sion-sparing strategies. Additionally, the application of predic-
Figure 3
Intensive care unit anemia point system Intensive care unit anemia point system. The correspondence between 
intensive care unit anemia points (see the text and Table 4) and proba-
bility for meeting criteria for late anemia is shown. For example, a surgi-
cal patient (11 points) with a lactate concentration of 4.0 g/dl (6 points) 
and a hemoglobin level of 9 g/dl (15 points) acquires 32 points, which 
corresponds to a risk of late anemia of 42.4%. The maximum score 
does not correspond to a probability of 1.00 because patients dying in 
the first week will never meet late anemia criteria.
Table 3
Receiver operator characteristics of predictive models
Model Receiver operator characteristic curve area






6-hour 0.75 0.72 0.77 0.74
24-hour 0.75 0.73 0.81 0.78
48-hour 0.76 0.74 0.84 0.82
72-hour 0.77 0.75 0.86 0.86
Late transfusion, transfused 7 days or more after admission to 
intensive care unit; late anemia, reached or would have reached 7.0 
g/dl at 7 days or more after admission to intensive care unit.
Table 4
The intensive care unit anemia score
Risk factor Pointsc




Each g/dl of hemoglobin less 
than 14 g/dla,b
3
aCalculated as the worst value at 6 hours after admission to intensive 
care unit. bIf baseline hemoglobin is 14 g/dl or more, the deficit is 0. 
cFor example, a surgical patient (11 points) with a lactate 
concentration of 4.0 g/dl (6 points) and a hemoglobin level of 9 g/dl 
(15 points) earns 32 points. From Figure 3, this corresponds to a risk 
of late anemia of 42.4%.Available online http://ccforum.com/content/10/1/R39
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tors in the form of a rule-based decision support tool resulted
in a much larger proportion of patients 'appropriately' receiving
intervention as opposed to more broad-based use and earlier
intervention than with existing trial inclusion criteria [5].
Although this exercise was theoretical, it has the potential to
increase the safe and cost-effective use of rHuEPO and other
transfusion-sparing strategies. Furthermore, we believe it is
illustrative of the potential opportunities for similar models for
other pre-emptive management strategies in the ICU.
The identification of candidates most likely to benefit from an
early intervention targeting late sequelae involves a trade-off
between accuracy and timeliness. In our models, including risk
factors from within 24, 48, or 72 hours of ICU admission, as
opposed to only the first 6 hours, improved discrimination, but
at a cost of a delays in starting the intervention. Similarly, using
existing clinical trial inclusion criteria to select patients for
intervention led to a delay of more than 2 days in treatment. For
an intervention such as rHuEPO, which takes days to begin to
show an effect, a delay of 1 or 2 days may be unacceptable.
For less time-sensitive pre-emptive strategies, such delays
may not be an issue. The importance of timeliness must be bal-
anced with that of accuracy, which becomes more important
as th erisk and cost of a particular intervention increase.
Clearly, identification strategies will need to be tailored for
each intervention.
Predicting late transfusion was consistently less accurate than
predicting late anemia. Given the substantial variation in trans-
fusion practices [9] it should not be surprising that predicting
transfusion was difficult. As transfusion practices become
more standardized and restrictive transfusion thresholds the
norm, the ability to predict transfusion is likely to become eas-
ier. However, as we have witnessed at our own institution,
even with strict enforcement of transfusion thresholds, there
are still many apparently unjustified transfusions that continue
to add unnecessary variation.
There are several limitations that deserve consideration.
Because of the retrospective nature of this study, we were not
able to determine why patients received blood transfusion.
Because so few hemoglobin concentrations ever fell to 7 g/dl
before transfusion, we had to extrapolate pre-transfusion
hemoglobin values to determine who would have reached 7 g/
dl by using the mean of individual slopes of hemoglobin con-
centrations. Although it might have been more accurate to
develop a predictive model using a large group of patients
whose hemoglobin concentrations actually fell to the thresh-
old, such a group does not exist, even among the 5,170 ICU
patients in our study. Importantly, the mean hemoglobin slope
after the acute phase (more than 3 days) used for this extrap-
olation (about 0.22 g/dl per day) was consistent with what oth-
ers have reported previously [7] and are therefore likely to be
a reasonable approximation. To develop our models we relied
on information obtained from several computerized databases,
an approach that would miss potential predictors that were not
recorded in these databases. This was a single-center study at
a tertiary-care academic medical center. It is possible that pre-
dictors of late anemia at this institution might vary from those
of other institutions, especially those with significantly different
case-mix or ICU practices. In light of this and because this
exercise was only intended to be theoretical at this point, the
ICU anemia point system should be validated in other cohorts
before being applied to routine patient care.
Conclusion
A rule-based decision support tool using information available
within six hours of ICU admission could lead to more appropri-
ate and timely use of transfusion-sparing interventions. In the
future, strategies to identify critically ill patients most likely to
benefit from pre-emptive therapies will become increasingly
important if therapies are to be used safely and cost-effec-
tively.
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Key messages
•  Identifying critically ill patients most likely to benefit from 
pre-emptive therapies will become increasingly impor-
tant if therapies are to be used safely and cost-effec-
tively.
•  By using information available within 6 hours of ICU 
admission, we were able predict the likelihood of late 
anemia with reasonable accuracy, suggesting a window 
of opportunity for the early identification of patients who 
might benefit from transfusion-sparing strategies.
•  The application of predictors in the form of a rule-based 
decision support tool resulted in a much larger propor-
tion of patients 'appropriately' selected for intervention.
•  A rule-based method has the potential to increase the 
safe and cost-effective use of rHuEPO and other trans-
fusion-sparing strategies in critically ill patients admitted 
to the ICU.